Healthcare Providers and Services
Company Overview of Sequenom Center for Molecular Medicine, LLC
Sequenom Center for Molecular Medicine, LLC, doing business as Sequenom Laboratories, operates as a diagnostics laboratory. It also develops a range of molecular genetic laboratory tests with a focus on prenatal and ophthalmological diseases and conditions. The company offers MaterniT21 PLUS test for fetal aneuploidies that analyzes the relative amount of 21, 18, 13, X and Y chromosomal material in circulating cell-free DNA from a maternal blood sample; Heredi-T cystic fibrosis carrier screen test that detects a phenotypically-confirmed panel selected from the John Hopkins CFTR2 database; SensiGene fetal RHD genotyping test for the analysis of fetal RHD genotype; and RetnaGene AMD test for a...
301 Michigan Street NE
Grand Rapids, MI 49503
Key Executives for Sequenom Center for Molecular Medicine, LLC
Vice President of National Accounts and Payor Strategies
Compensation as of Fiscal Year 2017.
Sequenom Center for Molecular Medicine, LLC Key Developments
Sequenom Laboratories Announces In-Network Contracts with Anthem Blue Cross and Blue Shield Plans
Mar 23 16
Sequenom Inc. announced that Sequenom Laboratories has entered into agreements with Anthem Blue Cross and Blue Shield Health Plans for the states of Connecticut, Maine, and New Hampshire, effective March 28, 2016. The agreements provide in-network coverage for Sequenom Laboratories noninvasive prenatal tests (NIPT) for both high and average-risk pregnancies to Anthem's members in those states.
Sequenom Center for Molecular Medicine, LLC Wins $3 Million Federal Contract
Jan 12 16
Sequenom Center for Molecular Medicine LLC, San Diego, announced that it won a $3 million federal contract from the U.S. Department of Veterans Affairs for medical laboratory testing and analysis services for the VA National Acquisition Center in Hines, Illinois.
Sequenom Laboratories Announces National Coverage Agreement with UnitedHealthcare Insurance Company for Prenatal Diagnostic Testing Services
Sep 17 15
Sequenom Laboratories announced that it has signed a national agreement with UnitedHealthcare Insurance Company, effective October 1, 2015, covering 43 million people throughout the United States, to provide the MaterniT21 PLUS, HerediT CF Carrier Screen and HerediT UNIVERSAL Carrier Screen laboratory-developed tests (LDT). The addition of this contract brings the number of covered lives under agreement by Sequenom Laboratories' diagnostic services to more than 200 million. The MaterniT21 PLUS test reports on trisomy 21, 18, 13, 16 and 22, sex chromosome aneuploidies, fetal sex and select microdeletions in single or multifetal gestations as early as 10 weeks in a pregnancy. Estimates suggest there are about 750,000 pregnancies at high risk for fetal chromosomal abnormalities each year in the United States. The HerediT CF Carrier Screening test analyzes the most clinically relevant mutations and variants related to cystic fibrosis. The HerediT UNIVERSAL Carrier Screening test is a comprehensive, customizable expanded test that screens for > 250 diseases and > 2,000 disease-causing mutations. These tests are available exclusively through Sequenom Laboratories as testing services provided to health care professionals.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|